💸 The Tape

Illinois just reminded everyone why it was one of the first states to get cannabis legalization right — and it's not done refining the model.

Governor JB Pritzker signed SB 3222 into law on Friday, enacting what amounts to the most significant overhaul of Illinois cannabis and hemp regulations since the state legalized adult-use sales in 2020. The omnibus bill passed the House 77-31 and the Senate 47-10, and it touches virtually every corner of the state's $1.5 billion cannabis industry — from consumer possession limits and dispensary operations to medical access, social equity, and the previously unregulated hemp-derived THC market.

"Illinois is taking action to protect consumers of all ages, especially children, from misleading packaging and labeling," Pritzker said. "This landmark legislation closes the intoxicating hemp loophole while bolstering equity and oversight and expanding medical access."

The Hemp Reckoning

The headline provision — and the one with the broadest implications — is the creation of the Illinois Hemp Act, a new regulatory framework that replaces the state's existing Industrial Hemp Act effective November 12, 2026. Starting immediately, the sale of intoxicating hemp products to anyone under 21 is banned. By November, those products — including Delta-8, THC-P, HHC, and other cannabinoids that have been sold largely outside the regulated cannabis market — will be reclassified as cannabis and brought under the state's Cannabis Regulation and Tax Act (CRTA).

That means licensed, tested, age-verified, and taxed — the same framework that governs every gram of cannabis sold through Illinois's licensed dispensary network. Products containing synthetic cannabinoids are prohibited entirely. Consumable and topical hemp products must meet the same safety, packaging, and labeling standards as regulated cannabis.

For the estimated hundreds of hemp retailers operating across Illinois — many of which have been selling intoxicating products with minimal oversight, no age verification, and packaging that has drawn criticism for appealing to minors — the November deadline represents either an adaptation or an exit. The unregulated hemp-derived THC market in Illinois has been operating in direct competition with licensed dispensaries that pay state taxes, maintain seed-to-sale tracking, and submit to regular inspections. SB 3222 closes that gap decisively.

What Changes for Licensed Operators

The bill delivers a long list of operational improvements that Illinois's licensed cannabis businesses have been requesting for years.

Possession limits double — adults over 21 can now hold up to 60 grams of flower (up from 30), 10 grams of concentrates (up from 5), and infused products with up to 1,000 mg of THC (up from 500). It's a common-sense adjustment that reflects actual consumer behavior and reduces the risk of low-level enforcement encounters for legal purchasers.

Dispensaries gain significant new flexibility. Drive-through and curbside pickup are now permitted — a format that took hold during COVID and has proven popular in other states but was previously not authorized in Illinois. Operating hours extend to 2:00 a.m., giving dispensaries the ability to serve late-night consumers who currently have no legal purchase option during those hours.

Medical cannabis certifications can now be issued via telehealth, reducing access barriers for patients in rural areas or those with mobility limitations. And critically, adult-use dispensaries can now register as medical cannabis dispensaries — a provision that carries enormous significance in the context of federal rescheduling.

Under the current Schedule III framework, only medical cannabis operations qualify for DEA registration and 280E tax relief. By allowing adult-use licensees to obtain companion medical licenses, Illinois is giving its operators a clear pathway to participate in the federal medical cannabis system — including eligibility for DEA registration that could position them for potential interstate commerce or other federal-level opportunities down the road.

Craft growers also benefit substantially. Canopy limits expand from 5,000 to 14,000 square feet — nearly tripling the growing space available to smaller cultivators who have struggled to achieve profitability at the prior scale. Combined with fee waivers and reduced security requirements for smaller operators, the bill represents a meaningful easing of the regulatory burden on exactly the businesses Illinois's equity-focused legalization model was designed to support.

Who Benefits Most

Illinois is home to several of the largest multi-state operators in the country, and SB 3222 creates advantages for the companies with the deepest operational footprints in the state.

Green Thumb Industries — headquartered in Chicago and operating RISE Dispensaries across the state — is arguably the most direct beneficiary. GTI already holds both medical and adult-use licenses in Illinois and has the infrastructure to immediately capitalize on expanded operating hours, drive-through capabilities, and increased possession limits that should drive higher average transaction values. The company's RYTHM and incredibles brands are among the most recognized in the state.

Cresco Labs, also Chicago-based, operates significant cultivation, processing, and retail operations in Illinois and holds No. 1 market share in the state through its branded CPG portfolio including Cresco, High Supply, and Mindy's. The ability to expand craft grower canopies and the elimination of hemp-derived competition both favor established operators with strong wholesale distribution.

Verano Holdings operates multiple Zen Leaf dispensaries across Illinois along with cultivation and processing facilities. The drive-through authorization and extended hours could meaningfully improve retail throughput at high-traffic locations.

Curaleaf and Ascend Wellness also maintain Illinois operations that stand to benefit from the regulatory cleanup — particularly the medical license companion provision that positions their facilities for DEA registration.

For social equity licensees — many of whom have struggled with high compliance costs and limited operating flexibility since entering the market — the fee reductions, relaxed security mandates, and expanded craft grower canopies represent the most tangible support the state has provided since the initial equity provisions were written into the 2019 legalization law.

The Bigger Picture

Illinois has generated over $4.4 billion in cumulative cannabis sales since legalization, producing more than $800 million in tax revenue. SB 3222 doesn't reinvent that market — it matures it. By closing the hemp loophole, expanding medical access, streamlining operations for licensed businesses, and positioning operators for federal integration through companion medical licensing, the bill prepares Illinois's cannabis industry for the post-Schedule III environment that is now arriving in real time.

Pritzker signed the original legalization law in 2019. Seven years later, he's still refining the framework — and still ahead of most states in doing so.

📈 Dog Walkers

$CGC ( ▼ 0.99% ) Keeps The Turnaround Going

Canopy Growth wants you to know it's not the same company that burned through billions and became the cannabis industry's most cautionary tale. The fiscal 2026 results suggest the turnaround is real — even if the destination remains a work in progress.

The company reported Q4 fiscal 2026 consolidated net revenue of $71.2 million, up 10% year-over-year, with full-year revenue reaching $284.6 million — a 6% increase over fiscal 2025. The growth engine was cannabis: cannabis net revenue jumped 20% in Q4 and 15% for the full year, driven by a 27% surge in Canadian medical revenue and 68% growth in international markets during Q4 as European supply chain issues were resolved.

CEO Luc Mongeau framed fiscal 2026 as a reset year — acquiring MTL Cannabis, modernizing innovation, and optimizing the business structure. The company now claims the position of Canada's leading medical cannabis provider by revenue, a title that carries real weight as federal rescheduling opens DEA registration pathways for medical operators.

The balance sheet transformation is arguably the most significant development. Canopy swung from net debt of $172.6 million at the end of fiscal 2025 to a net cash position of $131.3 million — a $303.9 million improvement. Free cash outflow narrowed from $176.6 million to $69.1 million. The company is still losing money — adjusted EBITDA loss was $20.2 million for the year — but the trajectory has improved meaningfully.

CFO Tom Stewart set the target: positive adjusted EBITDA during fiscal 2027, with improvements concentrated in the second half as MTL Cannabis integration completes.

The stock still carries the baggage of its history — the restatement disclosure, the Constellation write-downs, years of cash burn. But underneath the scar tissue, a smaller, leaner, medically-focused Canopy is starting to emerge. Whether the market gives it credit depends entirely on whether that EBITDA target gets hit.

$VREOF ( ▼ 0.56% ) To Acquire $CXXIF ( ▼ 2.21% )  

The relentlessly acquisitive multi-state operator announced a definitive agreement to acquire C21 Investments in an all-stock transaction, adding approximately 15 dispensaries and 158,000 square feet of cultivation and manufacturing capacity in Nevada. C21 shareholders will receive 0.023052 of a Vireo subordinate voting share for each C21 share held, with both boards unanimously approving the deal and Needham & Company providing a fairness opinion.

The strategic rationale centers on Nevada market dominance. C21 operates three of the highest-volume dispensaries in the state under its award-winning Silver State Relief brand, concentrated in northern Nevada — a geographic complement to Vireo's existing southern Nevada presence acquired through the Schwazze deal. CEO John Mazarakis said the combination "further extends our leading market share in Nevada" and is expected to generate meaningful synergies.

For Vireo, C21 is the latest in a staggering string of acquisitions that now includes Schwazze (Colorado and New Mexico), Eaze (California delivery), Hawthorne (from Scotts Miracle-Gro), the pending FLUENT deal (Florida), a Glass House retail joint venture (California), Bridgewell Agribusiness (organic food supply), and now C21 in Nevada. The company ended Q1 with $137.8 million in cash and has said explicitly it "expects to remain acquisitive."

C21 Chairman Bruce Macdonald framed the deal as giving shareholders access to Vireo's "scale, access to capital and broad market reach" — capabilities that smaller operators increasingly need as the industry consolidates under Schedule III economics.

The transaction requires two-thirds shareholder approval, court and regulatory sign-offs, and is expected to close in Q3 2026. A $3 million termination fee applies if C21 accepts a superior proposal.

At this pace, the question isn't what Vireo will buy next — it's what's left.

🗞️ The News

📺 Trade To Black

Virginia Cannabis Legalization Back On Track? | TDR Cannabis in 5

• Virginia Compromise: Lawmakers and Governor Spanberger have reportedly reached a deal through the state budget process to establish a framework for recreational cannabis sales beginning July 1, 2027 — just weeks after the governor vetoed the standalone sales bill.

• Key Issues Resolved: The agreement reportedly addresses the sticking points that killed the original legislation, including possession limits, taxation, public consumption rules, enforcement, and the launch timeline.

• Budget as Vehicle: By embedding cannabis provisions in the state budget — which must pass by July 1 — lawmakers found a path that's significantly harder for the governor to reject than a standalone bill she can veto without broader consequences.

• Five Years of Limbo Ending?: If the agreement holds, Virginia would finally resolve its unique contradiction — where adults can legally possess and grow cannabis but have no regulated way to purchase it — potentially making this one of the most significant state-level cannabis developments of the year.